Results 181 to 190 of about 128,993 (222)

Validation of a Size-Exclusion Chromatography Method for Bevacizumab Quantitation in Pharmaceutical Preparations: Application in a Biosimilar Study [PDF]

open access: yesSeparations, 2019
In May 2019, the Food and Drug Administration (FDA) proposed a quality range (QR) method for the comparative analytical assessment in biosimilar studies. In this process, several reference product lots are necessary, selected from a wide period of manufacturing dates with different shelf lives, to calculate the total variability expressed as the ...
Alexis Oliva, Matías Llabrés
exaly   +4 more sources

Addressing the health technology assessment of biosimilar pharmaceuticals

Current Medical Research and Opinion, 2010
Abstract The growing number of biosimilars presents challenges to regulatory and health technology assessment (HTA) systems. This paper illustrates these challenges by focusing on biosimilars used in the oncological setting. In particular, discordances between data required by regulatory and HTA authorities potentially deprive patients of effective ...
Alan, Stewart   +2 more
openaire   +2 more sources

Generic Medicines and Biosimilars: Impact on Global Pharmaceutical Policy

2020
Patient access to safe and cost-effective treatment is an important goal for the healthcare system. The development of biosimilar compounds and generic medicines is interesting to the industry and society to reduce healthcare costs, fulfill the needs of healthcare stakeholders and potentially increase accessibility to patients.
Ibrahim, Mohamed Izham Mohamed   +1 more
openaire   +3 more sources

The Future of Biosimilar Insulins [PDF]

open access: yesDiabetes Spectrum, 2016
IN BRIEF Biosimilar insulins are available in many countries and will be made available in the United States in the near future. Some concerns associated with biosimilar insulins include potential differences in the efficacy and safety between a ...
Ross Jason Bindler
exaly   +2 more sources

Chromatographic and electrophoretic assessment of Filgrastim biosimilars in pharmaceutical formulations

Journal of Pharmaceutical and Biomedical Analysis, 2014
An orthogonal testing protocol was developed and validated to assess the quality of Filgrastim biosimilars. Results were compared to those obtained from the innovator product. Initial screening was carried out using reducing and non-reducing gel electrophoresis.
Eman L, Shaltout   +3 more
openaire   +2 more sources

Quality by Design applications in biosimilar pharmaceutical products

Accreditation and Quality Assurance, 2008
A process is well understood when all critical sources of variability are identified and explained, variability is managed by the process design and monitoring, and product quality attributes are accurately and reliably predicted over the design space.
Ron S. Kenett, Dan A. Kenett
openaire   +1 more source

Gel Electrophoretic Methods for The Analysis of Biosimilar Pharmaceuticals Using The Example of Recombinant Erythropoietin

Bioanalysis, 2013
Due to their versatility and cost-effectiveness, gel electrophoretic methods provide an important set of tools for the analysis of therapeutic proteins. As an increasing number of biosimilar pharmaceuticals are entering the market, techniques are required that allow reliable demonstration of comparability of these products with the reference products ...
Christian, Reichel, Mario, Thevis
openaire   +2 more sources

Heterogeneity in Learning Processes and the Evolution of Dynamic Managerial Capabilities as a Response of Emergence of Biosimilar Market: Evidence From the Indian Pharmaceutical Industry [PDF]

open access: yesTechnology Analysis and Strategic Management, 2017
This paper examines heterogeneity in the response of Indian firms to the emergence of a new segment in the pharmaceutical generics market – biosimilars. The necessary diversity of the knowledge base and regulatory requirements underlying biosmilar products have created significant technological capability and market access challenges for Indian firms ...
Dinar Kale, Farah Huzair
exaly   +2 more sources

Biotechnological therapies and biosimilars for COVID-19: scarcities, poor regulation, and pharmaceutical black market: a case analysis in Ecuador

Generics and Biosimilars Initiative Journal, 2021
At the beginning of the COVID-19 pandemic, Ecuador was unprepared for the overwhelming number of COVID-19 cases. As the general population started to see the eff ects of the pandemic, unproven treatments and medications were sought by the population to try to ameliorate the impact of the pandemic.
Esteban Ortiz-Prado   +5 more
openaire   +1 more source

Home - About - Disclaimer - Privacy